7/102 sources · 2 publishersUpdated Oct 19, 14:55 UTC
Zealand Pharma reports safe and well‑tolerated Phase 1 results for Kv1.3 blocker ZP9830
Zealand Pharma said its investigational Kv1.3 ion channel blocker ZP9830 was safe and well‑tolerated in a four‑week Phase 1 trial, with no dose‑limiting safety issues or serious adverse events. The study also showed supportive pharmacokinetic data. The company will continue development with a Phase 1b study in plaque psoriasis and another autoimmune indication.
Why it matters
The company’s statement that the trial was safe reduces development risk and may support future funding or partnership opportunities, which could be reflected in the stock price.
Key facts
- 1The four‑week Phase 1 trial showed ZP9830 was safe and well‑tolerated, with no dose‑limiting safety issues. tradingview.com
- 2The trial demonstrated supportive pharmacokinetic results. tradingview.com
- 3No serious adverse events were reported in the Phase 1 trial. rttnews.com
- 4Zealand Pharma plans further trials of ZP9830 in plaque psoriasis and another autoimmune disease. rttnews.com
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.